Exhibit 99.2

STATEMENT OF OPERATIONS GAAP TO CASH ADJUSTMENTS BY LINE ITEM
July 1, 2010 — September 30, 2010

	Generic Segment										Brand Segment														(Gain)
								Total Generic										Total Brand							loss on										Total After-
	Other							Segment			Other							Segment							sale of		Interest			Total Pre-tax					tax
Expense Type	Revenue			COS		R&D		Adjustments			Revenue			COS		R&D		Adjustments		G&A			Amortization		assets		Expense			Adjustments		Tax Effect			Adjustments
Amortization	$	—		$	—	$	—	$	—		$	—		$	—	$	—	$	—	$	—		$	45.9	$	—	$	—		$	45.9	$	(12.2	)	$	33.7
Acquisition and licensing charges		(2.5	)		—		—		(2.5	)		—			—		6.0		6.0		(1.1	)		—		—		8.2	(1)		10.6		(1.1	)		9.5
Global supply chain initiative		—			4.6		3.8		8.4			—			—		—		—		0.6			—		—		—			9.0		(3.1	)		5.9
Legal settlements		—			—		—		—			—			—		—		—		89.9			—		—		—			89.9		(36.1	)		53.8
Asset sales/impairments		—			—		—		—			—			—		—		—		—			—		0.1		—			0.1		—			0.1
Segment Totals	$	(2.5	)	$	4.6	$	3.8	$	5.9		$	—		$	—	$	6.0	$	6.0	$	89.4		$	45.9	$	0.1	$	8.2		$	155.5	$	(52.5	)	$	103.0
I.R.S. audit settlement																																	(18.7	)		(18.7	)
Other tax items																																	(4.2	)		(4.2	)
																									(Gain)
																		Total							loss on
											Other							Segment							sale of		Interest			Total Pre-tax
											Revenue			COS		R&D		Adjustments		G&A			Amortization		assets		Expense			Adjustments
Totals by P&L Line Item											$	(2.5	)	$	4.6	$	9.8	$	14.4	$	89.4		$	45.9	$	0.1	$	8.2		$	155.5	$	(75.4	)	$	80.1
(1) Included within acquisition and licensing charges are interest accretion charges on the following obligations:
Atorvastatin contingent consideration obligation																											$	3.1
Manditorily Redeemable Preferred Stock																												3.8
Columbia contingent consideration obligation																												1.3
																											$	8.2